Long acting GLP-1 receptor agonist (injectable)
TG103 15 mg injection once weekly
TG103_SC_15MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.66 (0.01 to 54.90) | 0.58 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.68 (0.01 to 56.64) | 0.64 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.62 (0.80 to 33.36) | 0.41 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.05 (0.50 to 34.69) | 0.51 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.62 (0.47 to 15.47) | 0.39 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.67 (0.01 to 50.56) | 0.64 |